The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Intermedin (IMD), a member of calcitonin family, was suggested to play a role in angiogenesis and cancer. The aim of this study was to investigate the role of IMD in the angiogenic process and the underlying mechanism, and the possibility for it to be used as a target for angiogenesis-based anticancer therapies. Methods and Results-Using in vivo and in vitro 3-dimensional angiogenic models, we found that IMD induced a wellordered vasculature with hierarchical structure and had a synergistic effect with vascular endothelial growth factor. Using RNA interference, real-time polymerase chain reaction, and Western blot analysis, we found that IMD alleviated the undesirable effects of vascular endothelial growth factor by restricting the excessive vessel sprouting and uneven lumen formation through the regulation of vascular endothelial-cadherin and identified its receptor on the endothelial cells. Both mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase/Akt activation were involved in the effects. Furthermore, using experimental tumor models, we demonstrated that IMD was involved in tumor angiogenesis, and the blockade of IMD severely impaired blood supply and eventually inhibited tumor growth. Conclusion-We demonstrated that IMD played a critical role in the vascular remodeling process and tumor angiogenesis and may serve as a novel target for the development of angiogenesis-based anticancer therapies. (Arterioscler Thromb Vasc Biol. 2012;32:2721-2732.)
I ntermedin (IMD; also named adrenomedullin [ADM]-2) is a novel member of the calcitonin family that includes calcitonin, calcitonin gene-related peptide, amylin, and ADM. 1, 2 One of its family members, ADM, is an important endocrine and neurocrine integrator of homeostasis in the vascular system, performing diverse but important functions in physiogenesis and pathogenesis, including angiogenesis 3 and cancer. 4 Similar to ADM, IMD signals through the calcitonin receptor-like receptor/receptor activity modifying protein (CRLR/RAMP) complexes 2, 5 and performs vasodilatory and hypotensive actions, with potencies similar to or greater than ADM. 1, 2, 6 The similarities between IMD and ADM have raised the possibility that IMD may also have a role in angiogenesis and cancer.
Tumor vessels are distinct from normal vasculature because they are disorganized and tortuous. [7] [8] [9] However, although highly abnormal in morphology and structure, the tumor vasculature is still capable of supporting vigorous tumor growth. This paradox indicates the existence of intrinsic mechanisms that would control the process of vascular formation and improve the function of tumor vasculature to provide adequate blood supply for the aggressive tumor growth. A major question that remains to be elucidated is how endothelial cells coordinate their behaviors to form an ordered and functional vessel network.
Vessel sprouting and lumen formation are crucial to vessel network expansion and proper vascular function. 10, 11 In tumor vasculature, vessel sprouting is excessive and uncontrolled, forming a highly tortuous and nonproductive vasculature. Vascular endothelial growth factor (VEGF) is believed to be the most important factor for the stimulation of angiogenesis. [11] [12] [13] However, the overexpressed VEGF, especially in cancer, is also responsible for the vascular abnormalities and dysfunction. [7] [8] [9] 12 The VEGF/VEGF receptor 2 (VEGFR2) signaling cascade is required for the activation of quiescent endothelial cells to initiate vessel sprouting. 11 Thus, an elegant mechanism that fine-tunes the VEGF/VEGFR2 signaling cascade is the key to restrict excessive vessel sprouting.
Endothelial cells forming a monolayer with streamlined surface interconnected by cell-cell junctions are defined as quiescent endothelial cells. 11, 14 A major component of the adherens junctions, vascular endothelial (VE)-cadherin, has emerged as a critical regulator for the maintenance of endothelial cell quiescence by restraining the capacity of them to respond to VEGF. 11, [14] [15] [16] [17] The phosphorylation of VEGFR2 was markedly reduced in confluent endothelial cells but not in VE-cadherin null ones. 15, 17 This effect depends on the clustering of VE-cadherin on the surface of endothelial cells and the association of it with VEGFR2. [17] [18] [19] The complex composed of VE-cadherin and VEGFR2 inhibits the internalization of VEGFR2, resulting in decreased phosphorylation in response to VEGF stimulation. 17 Importantly, VE-cadherin is also crucial to the formation of vessel lumens. 11, 14, 16 Thus, VE-cadherin may serve as an intrinsic modulator to fine-tune the responsiveness of endothelial cells to VEGF for the formation of a relatively functional vasculature.
The phosphorylation of VEGFR2 activates multiple downstream pathways. The activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)1/2 is involved in endothelial cell proliferation, 20 and the phosphoinositide 3-kinase (PI3K)/Akt pathway is believed to be crucial in the regulation of endothelial cell survival, migration, and remodeling. 20, 21 VE-cadherin, VEGFR2, and PI3K form a multicomponent complex on the endothelial cell surface, the dissociation of which results in the inhibition of Akt phosphorylation. 18, 22, 23 Interestingly, it was reported that IMD was able to activate both the MAPK/ERK1/2 24 and PI3K/Akt pathways in myocardial 25 and endothelial cells. 24 In addition, IMD was involved in angiogenesis and VEGF/ VEGFR2 signaling cascade. 24 Furthermore, IMD was able to stabilize the endothelial barrier function via the maintenance of VE-cadherin on the cell surface. 26 Thus, IMD may serve as an integrator in the regulation of VE-cadherin and VEGF activities so as to affect the angiogenic process.
To test this hypothesis, we first used the in vitro 3-dimensional angiogenic models and Matrigel implant assay to determine whether IMD was involved in vessel sprouting and lumen formation, the key steps of angiogenesis, and to investigate the relationship between IMD and VEGF, the most important stimulator of angiogenesis. We then explored the underlying mechanisms and found that IMD restricted excessive vessel sprouting and promoted lumen expansion by alleviating the undesirable effects of VEGF via the regulation of VE-cadherin. Both ERK1/2 and Akt were involved in this effect. Finally, we demonstrated that IMD was involved in the normalization of tumor angiogenesis, and the blockade of IMD severely impaired blood supply and eventually inhibited tumor growth. This study provides novel insights to elucidate how endothelial cells coordinate their behaviors to form an ordered and functional vessel network and suggests that IMD may serve as a novel molecular target for the development of angiogenesis-based anticancer therapies.
Methods

Cells and Culture Conditions
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords and routinely grown in M199 (Gibco) supplemented with 10% fetal bovine serum (Hyclone). HUVECs between P3 and P4 were used for all experiments. Human skin fibroblasts were isolated from surgical specimens and cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum at 37°C and 5% CO 2 . Human skin fibroblasts between P5 and P20 were used for all experiments. A7r5 vascular smooth muscle cells, 4T1 mammary cancer cells, C26 colon cancer cells, SW620 human colon cancer cells, and A549 human lung cancer cells were obtained from American Type Culture Collection and routinely cultured according to American Type Culture Collection guidelines. The endothelial growth medium-2 and endothelial basal medium-2 (Clonetics) were used in the in vitro angiogenesis models, including tube formation and fibrin bead assay.
Antibodies and Peptides
Anti-CD31 was from BD Pharmingen. Anti-VEGF, anti-VEGFR2, anti-phospho-VEGFR2, anti-VE-cadherin, anti-ERK1/2, antiphospho-ERK1/2, anti-Akt, and anti-phospho-Akt were from Cell Signaling Technology. Anti-IMD polyclonal antibody was customized and purchased from Abgent. The peptides IMD and IMD were synthesized and purchased from Shinegene ( Figure I in the online-only Data Supplement).
Fibrin Bead Assay
An angiogenic sprouting and capillary lumen formation model using HUVEC-coated beads has been described in detail. 27 Briefly, dextran-coated Cytodex 3 beads (GE) were coated with HUVECs at a concentration of 400 HUVECs per bead. The following day, beads with cells were washed and resuspended at a concentration of 200 HUVEC-coated beads/mL in 2.5 mg/mL of fibrinogen (Sigma), with 0.15 U/mL of aprotinin (Sigma). Five hundred microliter of fibrinogen/bead solution was added to 0.625 U of thrombin (Sigma) in 1 well of a 24-well culture plate. Fibrinogen/bead solution was allowed to clot, and 2×10 4 human skin fibroblasts were plated on top of the gel clot. Medium was replaced every other day until desired growth is achieved. VEGF (50 ng/mL) was mixed in the fibrin gel and the medium in the VEGF group at day 0 and supplemented every other day when the medium was replaced. IMD (0.5 μmol/L) or IMD 17-47 (10 μmol/L) was added at day 4 and supplemented into the fresh medium every other day. The detailed protocol is described in Methods in the online-only Data Supplement.
Matrigel Implant Assay
Matrigel (BD pharmingen) was thawed on ice, and a concentration of 11 mg/mL and volume of 500 μL per plug were used. Matrigel plugs were subcutaneously injected into Balb/c mice. Mice were euthanized 2 weeks after implantation, and plugs were fixed in 4% paraformaldehyde, embedded in optimum cutting temperature compound, and cryosectioned and stained for CD31.
Western Blot Analysis
Cell extracts were separated by SDS-PAGE and electrotransferred onto polyvinylidene fluoride membranes. Membranes were blocked in 5% nonfat milk in Tris-buffered saline/0.01% Tween 20 for 2 hours. Blots were incubated at 4°C in Tris-buffered saline with primary antibody, followed by 1-hour incubation with horseradish peroxidaseconjugated secondary antibody (1:3000 dilution) and detected by a chemiluminescence kit (Millipore).
Real-Time RT-PCR
For the analysis of gene expression, total RNA was isolated from cells or tissues of interest using Trizol reagent (Invitrogen). Reverse transcription was performed with a Superscript II 2-Step reverse transcriptase polymerase chain reaction (RT-PCR) Kit (Invitrogen). Real-time RT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems). Gene expression was normalized to GAPDH. Relative expression differences represent the average±SEM. Three separate PCR was performed with triplicate reactions for each gene. The primers used were as follows-mouse IMD sense: 5′ CCTGGGCAAGGGACTGA 3′, antisense: 5′ CCACGAGGAATGGCTACAA 3′; human IMD sense: 5′ CGACCCGTCAAACGCATGGAG 3′, antisense: 5′ ACAGGCGGTG GCTGAGATTC 3′; human VE-cadherin sense: 5′ ATCGGTTGTTCAAT GCG 3′, antisense: 5′ AAAGCGTCCTGTTAGTCG 3′; human RAMP1 sense: 5′ GCTAACTACGATGCCCTACT 3′, antisense: 5′ AGAACCT GTCCACCTCCGAA 3′; human RAMP2 sense: 5′ GGGGACGGT GAAGAACTAT 3′, antisense: 5′ AAGCCCAGGTCAAACAACT 3′; human RAMP3 sense: 5′ GATGGGCAAGGTAAACG 3′, antisense: 5′ GACAGTCAGAACGACGGGTAT 3′.
siRNA Constructs and Delivery
Small interfering RNAs (siRNAs) for VE-cadherin and RAMP2 were purchased from Dharmacon (Chicago, IL). A scrambled nonsilencing siRNA that did not share sequence homology with any known human mRNA from a BLAST search was used as control for target siRNA, and the same sequence tagged with Cy5 was used for determining uptake and distribution in the transfected cells. In vitro transient transfection was performed according to the manufacturer's instruction using X-tremeGENE siRNA transfection reagent (Roche, CO).
Tumor Models
All animal experiments were approved by the Animal Ethics Committee of Sichuan University and performed according to institutional and national guidelines. Four T1 and C26 tumors were established in Balb/c mice. SW620 and A549 were established in nude mice. Mice at 6 to 8 weeks of age were injected subcutaneously with 2.5×10 6 tumor cells into the shaved right flank. The mice were treated by subcutaneous injection with IMD (1 mg/kg), IMD 17-47 (5 mg/kg) in saline, or saline alone twice a day, when the subcutaneous tumors were palpable. Tumor volume was determined by the following formula: tumor volume (mm 3 )=1/2×length (mm)×width (mm)×width (mm). Tumor suppression (%)=[(Tc−T 0 )−(Tx−T 0 )]/(Tc−T 0 )×100, 28 where T 0 is the initial tumor size at the beginning of drug treatment, Tc is the tumor size of the untreated control group on a given date, and Tx is the tumor size of the drug-treated group on a given date. Mice were anesthetized and euthanized at the end of the study, and tumors were collected for the following histological studies.
Immunohistochemical Analysis of IMD Expression and Tumor Vasculature
Tumor vessel labeling with lectin was performed to show blood perfusion, as described. 29 Briefly, mice were anesthetized, and 100 μL fluorescein Lycopersicon Esculentum lectin (Vector Laboratories) was injected through jugular vein and allowed to circulate for 15 minutes before systemic perfusion. The vasculature was then perfused transcardially with 4% paraformaldehyde in PBS for 10 minutes. Tumors were removed and postfixed by 4% paraformaldehyde for 2 hours, followed by an incubation in 30% sucrose overnight for cryoprotection and embedded in optimum cutting temperature compound (Sakura). Sections (10-40 μm thickness) were stained with anti-CD31 (1:50) as a marker of total vasculature (red). Paraformaldehyde-fixed and paraffinembedded tumor tissues were sectioned at 5 μm thickness and stained with anti-IMD (1:300). Detailed protocol is described in Methods in the online-only Data Supplement.
Image Analysis and Statistics
Immunostained sections were examined using Nikon TE2000 fluorescent microscope and photographed into TIFF images with SPOT color camera system (Diagnostic Instruments Inc). The images were analyzed using Image-Pro Plus analysis software (version 5.0.9.2). Vessel branching was analyzed by quantifying the number of branch points per field, and the tortuosity of vessels is defined as tortuosity=(length of vessel)/(straight line)−1, as described. 30 Signals from Western blot analysis and protein array were measured by photon emission and analyzed using Bio-Rad Quality One software (version 4.6.3). All values are expressed as mean±SEM. Statistical differences among groups were examined using the 2-tailed Student t test, and a P value <0.05 was considered statistically significant.
Results
IMD Stabilized Endothelial Cell Alignment and Induced Well-Organized Vasculature
To investigate the effects of IMD on vascular processes, we synthesized the mature IMD peptide and its truncated fragment IMD , which has been identified as a functional antagonist of IMD because of its competitive binding to IMD receptor CRLR/RAMP complexes but without residues 8 to 16 which are responsible for IMD bioactivity 2,31,32 ( Figure I in the online-only Data Supplement). HUVECs were seeded onto Matrigel-coated plates, where they started to form a capillarylike network after 2 hours of culture. This effect peaked around 6 hours of culture, after which the cells began to dissociate ( Figure 1A ). Treatment with IMD did not accelerate the process but stabilized the capillary-like network for 6 hours after tube formation ( Figure 1A ). The length of tubes decreased only by 10% in IMD-treated HUVECs compared with an ≈60% decrease observed in the controls ( Figure 1B ). This effect was abrogated by treatment with IMD 17-47 ( Figure 1A and 1B). The results indicated that IMD may play an important role in the maintenance of endothelial cell network stabilization.
We next investigated whether IMD may be involved in the major steps of angiogenesis, including sprouting, lumen formation, and anastomosis. Endothelial cells can align but cannot sprout or form lumens on the surface of Matrigel. Therefore, the fibrin bead assay was performed, in which HUVECs sprout from the surface of dextran-coated beads embedded in fibrin gels and form a distinct lumen-like structure. 27 As shown in Figure 1C , a complex web of vessels with hollow lumen had formed after 14 days of culture. IMD dramatically remodeled the morphology of the in vitro vasculature, which was well organized with relatively fewer sprouts ( Figure 1D ), wider lumens ( Figure 1E ), and more anastomosed vessels ( Figure 1F ) having a hierarchical architecture ( Figure 1C ). This effect was completely abrogated by treatment with IMD , which induced a chaotic vascular architecture with excessive sprouting and short and discontinuous vessels without obvious lumen-like structure ( Figure 1C-1F ). VEGF treatment alone significantly promoted vessel sprouting but caused the formation of a relatively unordered vasculature with uneven lumens and lack of connection with neighboring vessels ( Figure 1C-1F ). Interestingly, combined treatment of IMD and VEGF induced an ordered vascular network with reduced sprouts, increased lumen diameters, and fine interconnections ( Figure 1C-1F) .
To test the role of IMD in the in vivo angiogenesis model, VEGF, IMD, or IMD 17-47 was mixed with Matrigel and implanted subcutaneously into mice. VEGF stimulated angiogenesis as expected ( Figure 1G ). Interestingly, IMD markedly reduced the vessel density ( Figure 1H ), and combined IMD and VEGF induced a relatively straight and less tortuous network ( Figure 1I ), similar to that in the fibrin bead assay. The remodeling role of IMD was inhibited by IMD , which caused excessive sprouts and increased vessel density ( Figure 1G-1I ). These findings indicated that IMD had a unique remodeling role in the angiogenic process for the establishment of a well-ordered vessel system.
IMD Maintained Endothelial Cell Quiescence Through Regulation of VE-Cadherin
Of all the known angiogenic molecules, VEGF seems to be the most critical. [11] [12] [13] Using Matrigel implant and fibrin bead assay, we demonstrated that IMD alleviated some undesirable effects of VEGF, such as excessive vessel sprouting, which suggested that IMD may induce a state of endothelial cell quiescence. VE-cadherin is a major component of cell-cell adherens junction and has been shown to be critical for the vascular remodeling process and the maintenance of endothelial cell quiescence by restraining the capacity of the cells to respond to VEGF. 15 Using Western blot analysis, we found a 5.1-fold increase in VE-cadherin expression with the treatment of IMD for 24 hours (Figure 2A ). Real-time PCR analysis showed a significant increase in VE-cadherin mRNA both in sparse and in confluent HUVECs. This effect was blocked by either IMD or anti-IMD antibodies ( Figure 2B ). Furthermore, the HUVECs showed reduced phosphorylation of VEGFR2 with the stimulation of VEGF after treatment with IMD for 24 hours, indicating a state of cell quiescence as evidenced by restrained response to VEGF ( Figure 2C ). To determine whether VE-cadherin mediated the IMD-induced endothelial cell quiescence, we silenced VE-cadherin expression using siRNA ( Figure II in the onlineonly Data Supplement) and found that IMD lost its capacity to restrict VEGF-induced vessel sprouting ( Figure 2D ), to induce lumen formation ( Figure 2E ), and to induce low responsiveness to VEGF ( Figure 2F) . A time-course experiment showed that with the increasing time of IMD treatment, the responsiveness of HUVECs to VEGF decreased gradually. This effect could be blocked by VE-cadherin knockdown ( Figure  2G ). The effect was also dose-dependent. The concentration of IMD <0.1 μmol/L showed no effect on the phosphorylation of VEGFR2 ( Figure 2H ). In addition, the blockade of IMD with either IMD or anti-IMD disrupted the VE-cadherin clustering at the cell-cell contact ( Figure 2I ). We had hypothesized that IMD might have a direct effect on the VEGF/VEGFR2 signaling cascade. However, IMD did not affect VEGF expression ( Figure III in the online-only Data Supplement) and showed no direct effect on VEGFR2 signaling. Treatment with IMD for 24 hours showed no effect on VEGFR2 expression in HUVECs ( Figure 3A ). In addition, stimulation with IMD for 10 minutes had no effect VEGFR2 phosphorylation ( Figure  3B ). Furthermore, treatment of IMD and VEGF simultaneously did not inhibit VEGF-induced VEGFR2 phosphorylation in HUVECs. Blocking IMD did, however, cause phosphorylation of VEGFR2 ( Figure 3B ). Thus, our data indicated that IMD affects VEGF/VEGFR2 signaling via 2 indirect ways: upregulating VE-cadherin expression and sustaining its clustering at the endothelial cell surface.
ERK1/2 and Akt Activation Was Involved in the Remodeling Role of IMD on Vessel Morphogenesis
A complex composed of VE-cadherin and VEGFR2 inhibits the internalization of VEGFR2, resulting in decreased phosphorylation in response to VEGF stimulation 17 and subsequently inhibits downstream ERK1/2 phosphorylation. 14, 15, 17 We had hypothesized that IMD might inhibit the phosphorylation of ERK1/2. However, Western blot analysis showed that IMD induced a marked increase in ERK1/2 phosphorylation ( Figure 3C ), consistent with other observations. 24, 25 This effect was blocked by IMD (Figure 3C ). The results suggested that IMD affected the MAPK/ERK pathway, independent of VEGF/VEGFR2 signaling. However, IMD did not affect the proliferation of HUVECs ( Figure IV in the online-only Data Supplement). IMD may maintain the overall proliferation rate through the simultaneous upregulation of VE-cadherin and the activation of ERK1/2 signaling ( Figure V in the online-only Data Supplement). To investigate whether the IMD-induced morphogenetic changes of the vasculature was ERK1/2 dependent, we blocked the MAPK/ERK1/2 pathway with its inhibitor PD98059 and found that IMD was unable to induce vessel enlargement ( Figure 3E ) but still able to restrict vessel sprouting ( Figure 3F ). The result suggested that activation of ERK1/2 was required for IMD-induced lumen expansion but unnecessary for IMD-induced restriction of vessel sprouting.
It has been reported that IMD was able to activate PI3K/ Akt pathway in myocardial 25 and endothelial cells. 24 The dissociation of VE-cadherin clustering resulted in the inhibition of downstream Akt phosphorylation. 18, 22, 23 Together with our observations that IMD upregulated VE-cadherin expression (Figure 2A and 2B) and maintained its clustering ( Figure 2I ), we speculated that the remodeling role of IMD on the vascular morphogenesis may depend on the PI3K/Akt signaling cascade. To test this hypothesis, we blocked the PI3K/Akt pathway using its inhibitor Wortmannin and found that IMD lost its capability to reduce vessel sprouting ( Figure 3E ) or induce lumen expansion ( Figure 3F ). Western blot analysis showed that the treatment of IMD for 10 minutes upregulated the basal phosphorylation level of Akt, which could block IMD ( Figure 3D ). These results suggested that IMD affected both vessel sprouting and enlargement thorough the regulation of VE-cadherin and the downstream PI3K/Akt signaling pathway.
IMD Signaled Through CRLR/RAMP2 Receptor Complex
It has been reported that IMD was a nonselective agonist for CRLR/RAMP1, 2, or 3 receptor complexes. 2 However, RT-PCR analysis showed that only RAMP2, but not RAMP1 or RAMP3, was expressed in HUVECs ( Figure 3G ), which suggested that IMD may play its vascular remodeling role through CRLR/RAMP2 complex. To test this assumption, we used siRNA (siR-RAMP2) to knock down the expression of RAMP2 in HUVECs ( Figure II in the online-only Data Supplement). Real-time PCR analysis showed that IMD was unable to stimulate the expression of VE-cadherin ( Figure VI in the online-only Data Supplement) and the phosphorylation of ERK1/2 or Akt in RAMP2-silenced HUVECs (Figure 3H  and 3I ). In addition, the fibrin bead assay showed that IMD lost its capacity to restrict VEGF-induced vessel sprouting or facilitate lumen formation ( Figure 3J and 3K) . The results demonstrated that IMD signals through RAMP2 to regulate the behavior of endothelial cells and remodel the vasculature. Because there was endogenous IMD existing in this system, we further tested whether sprouting and lumen formation were affected by RAMP2 knockdown in the absence of exogenous IMD. The results showed that RAMP2 silencing did affect the vascular morphology, resulting in increased vessel sprouting ( Figure 3J ) and narrowed lumen diameter ( Figure 3K ).
IMD Normalized Tumor Vasculature
Here we sought to determine whether IMD is involved in tumor angiogenesis. We first evaluated the expression of , or anti-IMD, as indicated. The mRNA levels of VE-cadherin were measured using real-time polymerase chain reaction (PCR) and expressed relative to those in control cells. C, Untreated HUVECs or HUVECs pretreated with IMD for 24 hours were stimulated by VEGF for 10 minutes. The phosphorylation of VEGF receptor 2 (VEGFR2) was detected with anti-phospho-VEGFR2 and anti-VEGFR2. D and E, The HUVEC-coated beads were transfected with small interfering RNA (siRNA) of VE-cadherin (siR-VE-Cad) or scrambled nonsilencing siRNA (siR-Scram) and stimulated with VEGF with or without IMD. The number of vessel sprouts per bead (D) and the increase of vessel diameter (E) from day 7 to day 14 were quantified in 10 randomly chosen fields. ► indicates the vessel sprouts of each bead, and →((← denotes the vessel width. F, HUVECs transfected with siR-Scram or siR-VE-Cad were incubated with or without IMD for 24 hours and stimulated by VEGF for 10 minutes. The phosphorylation of VEGFR2 was detected with anti-phospho-VEGFR2. The fold change of phospho-VEGFR2 was expressed relative to those in control cells. G, The phosphorylation of VEGFR2 was examined using the lysates from HUVECs treated with IMD for 10 minutes, 24 hours, 48 hours, and 72 hours with siR-Scram or siR-VE-cad. H, The phosphorylation of VEGFR2 was examined using the lysates from HUVECs treated with a different dose of IMD with siR-Scram or siR-VE-cad. I, HUVEC monolayer treated with IMD (0.5 μmol/L), anti-IMD (15 μg/mL), or IMD IMD in clinical samples of human hepatocellular carcinoma. Strong expression of IMD was detected in the mesenchymal area in the tumor lesions. The expression of IMD was also found in murine 4T1 mammary cancer and C26 colon cancer isografts ( Figure 4A ). RT-PCR analysis showed that IMD was expressed in cultured endothelial cells and other stromal cells, including fibroblasts and vascular smooth muscle cells ( Figure 4B ). IMD mRNA was also detected in cultured 4T1, C26 cancer cell lines, and the lysates of their corresponding subcutaneous isografts ( Figure 4B) . The results suggested that stromal cells and some cancer cells themselves were the main sources of IMD in tumor lesions. Given that IMD was widely expressed in tumors and found to exhibit a unique vascular function in fibrin bead assay and Matrigel implant assay, we hypothesized that IMD may play a remodeling role in tumor angiogenesis as an autocrine/paracrine signaling molecule.
To test this hypothesis, we investigated the effects of IMD on vascular morphology in preclinical tumor models. C26 and 4T1 tumor-bearing mice were injected subcutaneously with saline, IMD, or IMD 17-47 after the tumors had become established. C26 tumors from the IMD 17-47 -treated mice exhibited a significant increase in vessel density, whereas tumors from mice treated with IMD exhibited decreased vessel density (Figure 4C and 4D) . The treatments elicited similar effects in the 4T1 isografts ( Figure VII in the online-only Data Supplement). In addition, IMD induced a less sprouted ( Figure 4E and 4F) and less tortuous ( Figure 4G ) vascular network. On the contrary, treatment with IMD 17-47 resulted in a much more tortuous and highly branched vasculature than that in the control tumors ( Figure 4E-4G) . The findings were similar to our observations in the Matrigel plug and fibrin bead assay, demonstrating that IMD normalized tumor vasculature by restricting vessel sprouting and reducing vessel tortuosity.
Blockade of IMD Inhibited Tumor Growth by Inducing Dysfunctional Vasculature
We next sought to determine whether the tumor growth was affected by IMD-induced vascular changes. Interestingly, despite the marked increase in vessel density, tumors from the IMD group were not substantially different in size from . Intermedin (IMD) activated extracellular signal-regulated kinase (ERK) 1/2 and Akt through calcitonin receptor-like receptor/receptor activity modifying protein 2 (CRLR/RAMP2) receptor complex. A, Western blot probed antivascular endothelial growth factor receptor 2 (VEGFR2) using lysates from human umbilical vein endothelial cells (HUVECs) treated with IMD for 24 hours. B, Western blot probed with anti-VEGFR2 and anti-phospho-VEGFR2 using the lysates from HUVECs treated with IMD, VEGF, or anti-IMD antibodies for 10 minutes. C, Western blot probed with anti-ERK1/2 and anti-phospho-ERK1/2 using the lysates from HUVECs treated with IMD or IMD 17-47 for 10 minutes. D, Western blot probed with anti-Atk and anti-phospho-Akt using the lysates from HUVECs treated with IMD or IMD 17-47 for 10 minutes. E and F, The HUVEC-coated beads were treated with IMD with or without PD98059 or Wortmannin. The increase in vessel diameter (E) and the number of vessel sprouts per bead (F) from day 7 to day 14 were quantified in 10 randomly chosen fields. G, The expression of RAMP1, 2, and 3 in HUVECs was detected by reverse transcriptase polymerase chain reaction (RT-PCR). H and I, HUVECs were transfected with scrambled nonsilencing small interfering RNA (siR-Scram) or siR-RAMP2 and stimulated with IMD for 24 hours. The fold change of phospho-Akt (H) and phospho-ERK1/2 (I) was expressed relative to those in control cells. J and K, The HUVEC-coated beads were transfected with siR-Scram or siR-RAMP2 and stimulated by VEGF with or without IMD. The number of vessel sprouts per bead (J) and the increase in vessel diameter from day 7 to day 14 (K) were quantified in 10 randomly chosen fields. All data are represented as mean±SEM of 3 independent experiments performed in duplicate wells. *P<0.05, **P<0.01, and ***P<0.001, respectively. control tumors, but treatment with IMD 17-47 resulted in a significant inhibition of tumor growth in both C26 and 4T1 cancer models ( Figure 5A ). Neither IMD nor IMD showed cytotoxic activity in the cultured cancer cell lines ( Figure  VIII in the online-only Data Supplement). The apparent paradox between vessel density and tumor volume raised the possibility that the excessive vessel sprouts caused by IMD blockade may be dysfunctional, resulting in reduced blood flow that was insufficient to support tumor growth. To test this notion, 29 mice were injected intravenously with fluorescein Lycopersicon Esculentum lectin to detect the perfused vessels. Treatment with IMD resulted in an increased overlap of lectin-labeled vessels and CD31-positive vessels, indicating that the vascular network was well perfused ( Figure 5B ). In contrast, treatment with IMD 17-47 resulted in decreased vessel function, as evidenced by a poorly perfused vasculature ( Figure 5B ). These findings demonstrated that the dysfunctional vasculature caused by the blockade of IMD severely impaired blood supply and eventually inhibited tumor growth. . Intermedin (IMD) was widely expressed in tumors and normalized tumor vasculature. A, Paraffin-embedded sections from human hepatocellular carcinoma (HCC) samples, 4T1 and C26 subcutaneous tumors were stained with anti-IMD, and signals were developed by 3,3′ diaminobenzidine chromogen (brown) and counterstained with hematoxylin (blue). B, Levels of IMD mRNA in different cell types and tumor lysates were expressed relative to that in human umbilical vein endothelial cells (HUVECs). C, Frozen sections of C26 tumors from mice treated with saline, IMD , and IMD were immunostained with anti-CD31 for the assessment of vessel density and vascular morphology. D, Quantification of the CD31-positive area was performed using Image-Pro Plus. E and F, Vessel branching was analyzed by quantifying the number of branch points (*) per field. G, The tortuosity of tumor vessels is defined as T=L/S−1, where L is the length of the vessel of interest and S is the straight line distance between its end points as described in the Methods section. All data are represented as mean±SEM (n=10). *P<0.05 and **P<0.01, respectively.
It has been reported that IMD could inhibit the food intake of rats. 2, 33 To rule out the possibility that the antitumor effects might be the consequence of body weight loss, we recorded the food intake and body weight of tumor-bearing mice every 2 days during the experiment. Both IMD and IMD suppressed food intake, which resulted in reduced body weight ( Figure 5C ). However, only IMD , not IMD, inhibited tumor growth ( Figure 5C ). The results demonstrated that inhibition of tumor growth did not result from body weight loss. The effect of IMD 17-47 on body weight may result from a nonspecific effect resulting from the antiangiogenic therapies, because systemic treatment with angiogenesis inhibitor has been shown to result in reduced food intake and bodyweight reduction, as well as adipose tissue loss in various models of obesity. 34, 35 We used 2 additional human tumor models and anti-IMD antibodies to further evaluate this tumor inhibitory effect. SW620 and A549 xenograft tumor models were established in nude mice and treated with IMD or anti-IMD. Subcutaneous injection with IMD 17-47 twice a day for 2 weeks led to 53% and 66% suppression of SW620 and A549 tumors ( Figure 5D and 5E). Intraperitoneal administration of anti-IMD every 2 days achieved 56% and 61% tumor suppression ( Figure 5D and 5E). Neither IMD 17-47 nor anti-IMD showed any effect on the growth of the cancer cell lines (data not shown). Together, we may conclude that the inhibition of tumor growth did not result from the cytotoxicity or body weight loss by the IMD inhibitors but instead was a result of the vascular dysfunction caused by the blockade of IMD.
Discussion
Naturally occurring angiogenesis is regulated by a tightly coordinated balance among the angiogenic regulatory molecules. However, this equilibrium is disturbed in some diseases, especially cancer, resulting in a structurally and functionally Figure 5 . Blockade of intermedin (IMD) inhibits tumor growth by inducing dysfunctional vasculature. A, Seven days after the C26 and 4T1 tumor cell inoculation, mice were subcutaneously injected with saline, IMD (1 mg/kg), or IMD 17-47 (5 mg/kg), respectively (n>9 for each group). B, Frozen sections of C26 tumors were stained by in vivo injection of fluorescein isothiocyanate (FITC)-conjugated tomato lectin through the jugular vein (green) to mark the perfused vessels and double stained with anti-CD31 (red) to mark all the vascular structures to visualize the effective perfusion of tumor vessels (green/red). The effective perfusion of tumor vessels from mice treated with IMD or IMD was expressed relative to the saline group. Effective perfusion rate is defined as EPR=P/T, where P is the FITC and CD31 double-positive vessels and T is the total vasculature (CD31-positive vessels). C, Top: The mean food consumption and body weight of the mouse treated with saline, IMD, or IMD 17-47 twice a day starting at day 6. Bottom: The growth curve and the tumor volume at day 16 before euthanasia (n=7 for each group). D and E, The SW620 and A549 xenografts were established in nude mice. When the subcutaneous xenografts were palpable (5 days after tumor inoculation), mice were subcutaneously injected with IMD 17-47 (5 mg/kg) or intraperitoneally injected with anti-IMD antibodies (5 mg/kg) (n=5 for each group). All data are represented as the means±SEM. *P<0.05 and **P<0.01, respectively. abnormal vasculature. 8, 9, 12 In this study, we identified a unique remodeling role for IMD in the normalization of tumor vasculature. Our data suggest an intrinsic mechanism by which IMD counteracts the vascular abnormality by alleviating the VEGF-induced undesirable effects, such as excessive vessel sprouting and uneven lumen formation. Our findings indicate that IMD works in coordination with VEGF to build a relatively normal and functional vasculature that will then provide adequate blood supply to support vigorous tumor growth.
The formation of a functional vasculature needs to precisely control the processes of vessel sprouting and lumen formation. However, the overexpressed VEGF in tumors disturbs the processes, leading to uneven vessel diameter and excessive vessel sprouts without proper vascular function. 8, 9, 12 The initiation of vessel sprouting needs to activate the quiescent endothelial cells, which requires VEGFR2 activation. 11 IMD showed no direct effects on the expression of VEGFR2 or its phosphorylation but indirectly restrained the endothelial cell response to VEGF by upregulating VE-cadherin expression and sustaining its clustering. It is well documented that VE-cadherin, VEGFR2, and PI3K form a multicomponent complex on the endothelial cell surface, the dissociation of which results in the internalization and phosphorylation of VEGFR2 17 and the inhibition of Akt phosphorylation. 18, 22, 23 Thus, by maintaining the VE-cadherin/VEGFR2/PI3K complex, IMD attenuated the internalization and phosphorylation of VEGFR2, but on the other hand activated the PI3K/Akt signaling cascade. IMD also induced ERK1/2 phosphorylation, independent of VEGF/ VEGFR2 pathway. The blockade of MAPK/ERK pathway deprived the ability of IMD to induce proper lumen formation. Taken together, we may conclude that IMD is an endogenous angiogenic regulator that is critical for vascular normalization through the regulation of VE-cadherin and the downstream Akt and ERK1/2 pathways ( Figure 6A) .
The blockade of IMD transmitted a series of false signals to the vasculature ( Figure 6B ). The endothelial cells were unable to sense the normally secreted IMD via CRLR/RAMP2 receptor, resulting in decreased expression of VE-cadherin and dissociation of VE-cadherin/VEGFR2/PI3K complex, which indirectly elevates the endothelial cell response to VEGF stimulation, resulting in phosphorylation of VEGFR2 and subsequent excessive vessel sprouting. In addition, with the existence of IMD or anti-IMD, the normally secreted IMD was unable to activate Akt or ERK1/2 signaling cascade. Thus, the excessive vessel sprouts lacked necessary proliferation signals and lost the ability of proper lumen formation and eventually formed Figure 6 . Schematic overview of intermedin (IMD) signaling in endothelial cells. A, The paracrine or autocrine IMD signals through calcitonin receptor-like receptor/ receptor activity modifying protein 2 (CRLR/RAMP2) receptor complex and maintains a complex composed of vascular endothelial (VE)-cadherin, vascular endothelial growth factor receptor 2 (VEGFR2), and phosphoinositide 3-kinase (PI3K) by inducing the expression of VE-cadherin and sustaining its clustering on the endothelial cell surface. The PI3K/Akt pathway is then activated, but the internalization and phosphorylation of VEGFR2 are inhibited. IMD also induces the phosphorylation of extracellular signal-regulated kinase (ERK1/2), independent of VEGF/VEGFR2 signaling. B, With the existence of IMD or anti-IMD, the endothelial cells were unable to sense the normally secreted IMD via CRLR/RAMP2 receptor, resulting in decreased expression of VE-cadherin and dissociation of VE-cadherin/VEGFR2/PI3K complex, which results in internalization and phosphorylation of VEGFR2 and the inhibition of PI3K/Akt pathway. The blockade of IMD also inhibits the phosphorylation of ERK1/2. highly sprouted but nonfunctional vessel system ( Figure 6B) . These results suggest a potential therapeutic strategy for the treatment of cancer. Previous antiangiogenic treatment of tumors has mainly aimed for direct inhibition of angiogenesis. Our findings using IMD blockade suggest an alternative approach to treat tumors by inducing dysfunctional vasculature. This notion is consistent with previous reports that have demonstrated that blockade of the Dll4-Notch pathway compromises tumor vasculature function by causing excessive but nonproductive angiogenesis, which in turn inhibits tumor growth. 29, 36 Herein, we used IMD as the treatment agent to block the IMD/RAMP2 signaling cascade in mouse tumor models. IMD was reported to be a competitive antagonist of IMD, because it has the capability to bind CRLR/RAMP receptor complex but lacks 8 to 16 amino acid residues in N terminus, which are responsible for the bioactivity of IMD. 2, 5 There were some concerns that IMD might not be a complete antagonist of IMD. However, we found that almost all the bioactivities of IMD on endothelial cells, such as reducing vessel sprouts, promoting lumen expansion, and inducing well-ordered vasculature, could be inhibited by IMD . In addition, IMD was able to block IMD-induced VE-cadherin expression and Akt and ERK1/2 phosphorylation in HUVECs. Thus, although we cannot yet 100% rule out the possibility that IMD 17-47 still has some agonist activities, we believe that IMD 17-47 could at least serve as a functional antagonist of IMD for the blockade of its vascular bioactivities.
In this study, we showed that IMD decreased the tumor vessel sprouts and density, seemingly discrepant from previous study, in which the ischemic hindlimb was used as an in vivo angiogenic model. 24 This is essentially a physiological model, in which the microenvironment is normal, and the angiogenic process is tightly controlled by the balance of pro-and antiangiogenic factors. However, tumor vasculature is highly abnormal and tortuous resulting from the scrambled angiogenic process. Thus, the different observations in vessel density were likely a result of the very different microenvironment between the 2 models. In this study, we found that IMD did not affect VEGF expression and showed no direct effect on VEGF/VEGFR2 signaling. Although IMD activated ERK1/2 pathway, it did not affect the overall proliferation rate of endothelial cells. Thus, based on the traditional view, it is hard to determine whether IMD belongs to the pro-or antiangiogenic factors. However, if we take the vessel function as a standard, IMD should be defined as a proangiogenic factor, because treatment of IMD significantly improved the blood perfusion of the vasculature, consistent with previous observations. 24 Thus, our data are not discrepant from previous findings but supported the idea that IMD is an new angiogenic growth factor in a novel way.
Of all the known angiogenic molecules, VEGF seems to be the most critical. 12, 13 The anti-VEGF treatments are based on the concept of starving the tumor by destroying existing vessels and preventing new vessel growth. 11 Thus, the combination of anti-VEGF agents and IMD inhibitors may be more effective in the treatment of cancer, because the established tumor vasculature might be destroyed by anti-VEGF agents and the newly formed vessels might be dysfunctional with the treatment of IMD inhibitors. The combination with IMD inhibitors might represent a promising strategy for treating tumors, where anti-VEGF therapy alone is less effective.
The complex processes regulating tumor angiogenesis are still not completely understood. The study described herein provides evidence that IMD played a unique role in vascular remodeling and normalization through the IMD-RAMP2 signaling axis that may significantly alter tumor growth and drug sensitivity. Our data further elucidate the molecular and cellular mechanisms of the vascular normalization process. The general importance of IMD in the vasculature, especially in tumor angiogenesis, may have a potential to be developed as novel therapeutic strategies for cancer therapy.
